628 results on '"Osaki, Yukio"'
Search Results
2. Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study
3. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
4. Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child–Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance
5. Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag
6. Serum Levels of α-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma
7. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma
8. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
9. 膵頭十二指腸切除術後の膵管空腸吻合部ロストステントの閉塞が発症原因と考えられた膵膿瘍に対して経胃的ドレナージが奏功した1例
10. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures
11. P30-1 Comparison of efficacy of atezolizumab and bevacizumab treatment for hepatocellular carcinoma between tyrosine kinase inhibitor-naive and -experienced patients
12. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation
13. Factors predicting through-the-scope gastroduodenal stenting outcomes in patients with gastric outlet obstruction: a large multicenter retrospective study in West Japan
14. Expansion of viral variants associated with immune escape and impaired virion secretion in patients with HBV reactivation after resolved infection
15. First-Line Gemcitabine, Nab-Paclitaxel, and Oxaliplatin Chemotherapy With Itraconazole in Patients With Metastatic Pancreatic Cancer: A Single Institution Experience
16. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
17. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial
18. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection
19. Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double‐blind, controlled trial
20. Screening and surveillance for occupational cholangiocarcinoma in workers exposed to organic solvents
21. Gastric atrophy and xanthelasma are markers for predicting the development of early gastric cancer
22. A Dumbbell-Shaped Hyperechoic Mass in the Common Hepatic Artery Swinging With the Heartbeat
23. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial
24. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
25. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
26. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study
27. Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents
28. Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments
29. Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma
30. Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside/nucleotide analog therapy
31. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan
32. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review
33. Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy
34. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes
35. Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers
36. Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases
37. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study
38. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation
39. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer
40. Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma
41. Gastric xanthelasma may be a warning sign for the presence of early gastric cancer
42. Effect of treatment with branched-chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma
43. Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma
44. Dense-type crypt opening seen on magnifying endoscopy with narrow-band imaging is a feature of gastric adenoma
45. Clinical characteristics of collagenous colitis with linear ulcerations
46. Transcatheter Arterial Chemoembolization (TACE) with Lipiodol to Treat Hepatocellular Carcinoma: Survey Results from the TACE Study Group of Japan
47. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels
48. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)
49. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B1
50. Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.